期刊文献+

欧盟药物警戒数据库功能升级与思考 被引量:5

Upgrade of Eudra Vigilance in the EU and Its Considerations
下载PDF
导出
摘要 目的对欧盟药物警戒数据库主要功能及其升级情况进行介绍,为促进我国现有不良反应监测工作发展提供思考和借鉴。方法采用文献分析法,围绕欧盟药物警戒数据库(Eudra Vigilance)的2017年年度报告内容,介绍了目前该数据库的主要功能及其升级情况。结果欧盟药物警戒数据库对通过审查的新功能、内置的药品信息词典及医学文献监测等内容进行了升级和强化。结论借鉴欧盟药物警戒数据库功能升级经验,我国药品不良反应监测系统在数据格式的国际化、扩大数据共享范围及完善药品信息数据库等方面可进一步加强。 Objective To introduce the main and upgraded features of EudraVigilance,so as to provide consideration and reference for the development of our national ADR monitoring in China.Methods Based on 2017 Annual Report on EudraVigilance for the European Parliament,the council and the commission,the new and enhanced functionalities of this database were analyzed.Results The enhanced functionalities of this database were mainly focused on functionalities subject to audit,the dictionary for medicinal product information and medical literature monitoring,etc.Conclusion The adverse reaction monitoring system in China still needs to be strengthened in internationalization of data formats,expansion of data sharing and improvement of drug information database.
作者 王涛 王丹 范燕 董铎 WANG Tao;WANG Dan;FAN Yan;DONG Duo(Center For Drug Reevaluation,CFDA,Beijing 100022,China)
出处 《中国药物警戒》 2018年第7期411-413,418,共4页 Chinese Journal of Pharmacovigilance
基金 国家科技重大专项项目(2017ZX09101001-001-003):药品再评价政策法规及实施策略研究
关键词 人用药品 数据库 功能 药物警戒 medicines for human use database function pharmacovigilance
  • 相关文献

参考文献5

二级参考文献43

  • 1European Medicines Agency. EudraVigilance access policy formedicines for human use(08/07/2011)[S].(2012-10-12)[2013-06-01]iittp://eudravigilance.ema.europa.eu/human/EudraViglanceAc-cessPolicy.asp]. 被引量:1
  • 2European Medicines Agency. Pharmacovigilance legislation [EB/OL].(2014-01-01)[2014-07-28].http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000491.jsp&mid=WC0b01ac058058f32d. 被引量:1
  • 3European Medicines Agency.GVPModule VI Management and re-porting of adverse reactions to medicinal products [EB/OL].(2012-06-22) [ 2014-08-23 ]. http: //www. ema. europa. eu/docs/en_GB/document_Hbrary/Scientific__guideline/2012/06/WC500129135.pdf. 被引量:1
  • 4European Medicines Agency.IME list based on MedDRA version17.0 [EB/OL]. (2014-03-05)[2014-08-23].http://eudravigilance.ema.europa.eu/human/textforIME.asp. 被引量:1
  • 5European Medicines Agency.ICH Topic E 2 DPost Approval SafetyData Management[EB/OL].(2004-05-01)[2014-08-23]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guide-line/2009/09AVC500002807.pdf. 被引量:1
  • 6European Medicines Agency.Inclusion/exclusion criteria for the"Important Medical Events" list[EB/OL]. (2014-03-05)[2014-08-23].http://eudravigilance.ema.europa.eu/human/docs/IME/IME%20criteria%20vl7%200.doc. 被引量:1
  • 7World Health Organization, WHO Collaborating Centre for DrugMonitoring. The importance of Pharmacovigilance. Safety monito-ring of medicinal products [ S]. 2002. 被引量:1
  • 8EDWARDS IR. Spontaneous reporting-of what? Clinical concernsabout drugs [ J]. Br J Clin Pharmacol, 1999 , 48 : 138 - 141. 被引量:1
  • 9European Medicines Agency. EudraVigilance access policy forvb-medicines for human use ( 08/07/2011 ) [EB/OL]. (2012 -10- 12) [2013 -06 -01]. http://eudravigilance. ema. europa.eu/huraan/EudraViglanceAccessPolicy. asp. 被引量:1
  • 10HAMMOND IW, RICH DS, GIBBS TG. Effect of consumer re-porting on signal detection: using disproportionality analysis[ J].Expert Opin Drug Saf,2001,6(6) : 705 -712. 被引量:1

共引文献60

同被引文献38

引证文献5

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部